The American journal of managed care · 2025
HEDIS glycemic goal achieved using control-IQ Technology.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Patel Bimal V, Wang Sharon M, Messer Laurel H, Pinsker Jordan E, Polin Miranda R, Hirsch Irl B, Ekhlaspour Laya, Edelman Steve, Brixner Diana I, Stemple Charles
Аннотация
OBJECTIVES: This analysis evaluated changes in glucose management indicator (GMI) at 12 months from baseline hemoglobin A1c (HbA1c)-which are both used interchangeably in the Healthcare Effectiveness Data and Information Set (HEDIS) quality measures for glycemic status-in individuals with type 1 diabetes (T1D) who switched from multiple daily insulin injections (MDI) to Control-IQ technology, an automated insulin delivery (AID) therapy.
STUDY DESIGN: US-based retrospective analysis that used data from the Tandem Diabetes Care, Inc t:connect web application and customer relationship management database.
METHODS: Inclusion criteria were having had prior treatment with MDI, having started Control-IQ at least 1 year prior to the study end date, having a most recent recorded baseline HbA1c measurement within 6 months prior to AID initiation, and having at least 70% continuous glucose monitoring use during the 12-month postinitiation period. The primary outcome was the change in number and proportion of individuals who met the HEDIS quality measure (HbA1c or GMI of < 8% [control] or > 9.0% [poor control]) and American Diabetes Association (ADA) glycemic target (< 7%) according to payer type (commercial, Medicaid, Medicare) during the 12-month observation.
RESULTS: The analysis included 12,522 individuals with T1D. Following AID initiation, the number and proportion of individuals who met the HEDIS quality standard increased from 6205 (49.6%) to 11,632 (92.9%) at 12 months (∆ = 87.5%). Similar improvements were observed among those who achieved less than 7% GMI. Within all payer groups, the number of patients with baseline HbA 1c levels greater than 9% decreased from 3431 to 15 (∆ = -99.6%).
CONCLUSIONS: A greater proportion of individuals can achieve the HEDIS and ADA target goals for glycemic status with Control-IQ use compared with MDI use across all payer types.
STUDY DESIGN: US-based retrospective analysis that used data from the Tandem Diabetes Care, Inc t:connect web application and customer relationship management database.
METHODS: Inclusion criteria were having had prior treatment with MDI, having started Control-IQ at least 1 year prior to the study end date, having a most recent recorded baseline HbA1c measurement within 6 months prior to AID initiation, and having at least 70% continuous glucose monitoring use during the 12-month postinitiation period. The primary outcome was the change in number and proportion of individuals who met the HEDIS quality measure (HbA1c or GMI of < 8% [control] or > 9.0% [poor control]) and American Diabetes Association (ADA) glycemic target (< 7%) according to payer type (commercial, Medicaid, Medicare) during the 12-month observation.
RESULTS: The analysis included 12,522 individuals with T1D. Following AID initiation, the number and proportion of individuals who met the HEDIS quality standard increased from 6205 (49.6%) to 11,632 (92.9%) at 12 months (∆ = 87.5%). Similar improvements were observed among those who achieved less than 7% GMI. Within all payer groups, the number of patients with baseline HbA 1c levels greater than 9% decreased from 3431 to 15 (∆ = -99.6%).
CONCLUSIONS: A greater proportion of individuals can achieve the HEDIS and ADA target goals for glycemic status with Control-IQ use compared with MDI use across all payer types.